Brief: Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
15/07/2024 13:33
July 15 (Reuters) - Lantheus Holdings Inc LNTH.O :
* LANTHEUS ACQUIRES NAV-4694, A NEXT-GENERATION ß AMYLOID
PET
IMAGING AGENT FOR ALZHEIMER’S DISEASE
* LANTHEUS- UNDER TERMS, LANTHEUS WILL PROVIDE AN UPFRONT
PAYMENT
AS WELL AS POTENTIAL ADDITIONAL DEVELOPMENT AND COMMERCIAL
MILESTONE PAYMENTS
* LANTHEUS HOLDINGS INC - LANTHEUS WILL MAKE ROYALTY
PAYMENTS FOR
RESEARCH REVENUE AND COMMERCIAL SALES
* LANTHEUS HOLDINGS INC - ACQUIRES MEILLEUR TECHNOLOGIES
Source text for Eikon: ID:nGNX8xBTqk
Further company coverage: LNTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsStreet View: Lantheus' tumor kit setback seen as temporary, with growth catalysts still ahead
Brief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say